Navigation Links
Patients in Europe benefit from new radiation therapy
Date:10/29/2009

A new, innovative form of radiation based on verified scientific facts will be available to patients all over Europe within the next few decades. The official kick-off meeting of the Community project ULICE (Union of LIght Ions Centres in Europe), which the European Union is supporting with nearly 10 million euros, was held in fall 2009 in the Department of Radiooncology and Radiation Therapy of the Heidelberg University Hospital. This consortium consists of a total of 21 European research and treatment facilities in the field of ion therapy who have joined forces in an interdisciplinary network in order to advance basic research in the fields of physics, biology and medicine, and to effectively use the existing ion therapy facilities in Europe in a joint effort to further develop this technique.

Transnational clinical studies

The project as a whole is divided into three programs:

  • Patients will be treated in the context of joint transnational clinical therapy studies in ion therapy facilities. This project is to be coordinated and directed from Heidelberg, where patient assignment and indications will be structured and established, and transnational and transinstitution databases for clinical and preclinical parameters will be established.
  • The second program will consist of the research and further development of ion therapy in the various clinical and preclinical sub-areas in focus; these joint research activities will be centrally coordinated from Vienna.
  • The third program will focus on communication and interaction as well as interdisciplinary discussion and consensus building, and will be centrally directed by the European Organization for Nuclear Research (CERN) in Geneva.

Four primary project directors will be responsible for the project: Prof. Dr. Roberto Orrechia, Medical Director of Radiooncology and the National Center for Hadron Therapy (Centro Nazionale di Adroterapia Oncologica, CNAO) in Milan, Prof. Dr. Richard Ptter, Medical Director of the Department of Radiooncology and Radiation Therapy at the General Hospital (AKH) of Vienna, Prof. Dr. Manjit Djosanjh of the European Organization for Nuclear Research (CERN) in Geneva, and Prof. Dr. Dr. Jrgen Debus, Medical Director of the Department of Radiooncology and Radiation Therapy at the Heidelberg University Hospital.

A total of 22 centers of excellence in Europe involved

In addition to the four centers of excellence (Heidelberg, Milan, Geneva and Vienna), a total of 18 other European centers will be included in the joint project. Essential preliminary work has already been completed, especially in Berkeley, California, USA and at the GSI Helmholtz Center for Heavy Ion Research in Darmstadt, Germany. So far, more than 70,000 patients all over the world have been treated with ion radiation, most of them with protons and heavy ions. Heavy ions (carbon ions) differ from conventional photon radiation therapy and proton therapy by an increased relative biological effectiveness (RBE), which has shown critical therapeutic advantages, especially for slow-growing and radiation-resistant tumors.

Since 1997 far more than 400 patients have been treated by the Heidelberg radiooncologists with carbon ions in cooperation with the GSI Helmholtz Center for Heavy Ion Research in Darmstadt and the Department of Medical Physics at the German Cancer Research Center (DKFZ) in Heidelberg, as well as the Rossendorf Research Center in Dresden. Therapeutic results have been significantly improved, especially for tumors at the base of the skull.

Heidelberg Ion Radiation Therapy Center is opened

Based on this preliminary work, the Heidelberg Ion Radiation Therapy Center (HIT) has been set up at the Heidelberg University Hospital and will soon begin clinical operation. There, it will be possible to treat over 1,300 patients per year with ion radiation. In particular, tumors of the base of the skull such as chordomas, chondrosarcomas and meningiomas as well as tumors of the salivary glands and prostate carcinomas will be treated. Brain tumors such as glioblastomas and low-grade astrocytomas will also be treated in the context of clinical studies at the HIT.


'/>"/>

Contact: Dr. Juergen Debus
Juergen.Debus@med.uni-heidelberg.de
49-062-215-68202
University Hospital Heidelberg
Source:Eurekalert

Related biology news :

1. ICU patients on ventilators flex and stretch in study at Case Western Reserve University
2. Improved diet and exercise alone unlikely to cure obstructive sleep apnea in obese patients
3. Research needed to learn which DCIS patients may be candidates for less invasive therapy
4. Revolutionary drug could be new hope for adrenal cancer patients
5. USDA grant to educate AIDS patients about food safety
6. Stimulus funding helps K-State biochemist study eyes lens in diabetes, galactosemia patients
7. Study shows cancer vaccines led to long-term survival for patients with metastatic melanoma
8. Probiotics help gastric-bypass patients lose weight more quickly, Stanford study shows
9. Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients
10. Harvard scientists solve mystery about why HIV patients are more susceptible to TB infection
11. Study characterizes eczema patients most at risk for dangerous viral infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... Calif. , Dec. 6, 2016  SRI ... to $150 million from the National Institutes of ... and the Division of AIDS (NIAID-DAIDS) to support ... other non-vaccine pre-exposure (PreP) agents. Under the seven-year ... preclinical product development services for candidate HIV-prevention products ...
(Date:12/5/2016)... , Dec. 5, 2016 Axovant Sciences Ltd. ... company focused on the treatment of dementia, today announced ... the treatment of Alzheimer,s disease will be presented at ... on Friday, December 9, 2016 in San ... results of both simple and complex measures of activities ...
(Date:12/5/2016)... ... ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility in ... Lubinski will be traveling to Germany on December 6th. Mr. Lubinski will meet ... discuss the benefits of a viscoelastic total disc replacement. , AxioMed received its ...
(Date:12/5/2016)... RAPIDS, Mich. , Dec. 5, 2016 NxGen MDx announced ... "By bringing the test in house, we,ve been able to improve customer ... down for patients," says Alan Mack , CEO of NxGen MDx. ... , , ... in test volume has led to more job opportunities at the Grand ...
Breaking Biology Technology: